Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIDOA: Tocilizumab in Refractory Hand Osteoarthritis
NCT02477059Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2015
- Primary completion
- Dec 2018
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hand osteoarthritis comparing Tocilizumab with Placebo (2 arms). Primary endpoint: Change of pain (VAS) at 6 weeks. Started Nov 2015; status: completed.
02
Drugs
tocilizumab
03
Conditions
hand osteoarthritis
Beyond the preview
Go deeper on NCT02477059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02477059.